癌症的发病率和死亡率在全球范围内每年都在增加，但癌症患者的生存率仍然不尽人意。因此，有必要进一步阐明参与肿瘤发展和药物耐药的分子机制，以改善癌症的治愈率或生存率。近年来，自噬在肿瘤学研究领域成为热门话题，在肿瘤发生、进展和药物耐药中发挥着双刃剑的作用。同时，长链非编码RNA(lncRNA)也被证明能够调节自噬，而自噬的双面性决定了自噬相关lncRNA(ARlncRNA)的双重调控作用。因此，ARlncRNA可以作为不同癌症的有效治疗靶点。此外，ARlncRNA在肿瘤组织中的丰度和稳定性使其成为有前景的生物标志物。在本综述中，我们总结了ARlncRNA在肿瘤细胞增殖、凋亡、迁移、侵袭、药物耐药、血管生成、放射耐药和免疫调节中的作用和机制。此外，我们描述了这些ARlncRNA的临床意义，包括作为生物标志物/治疗靶点以及与临床药物的相关性。©2023年作者发表。由KeAi Communications Co. Ltd.代表Elsevier B.V.提供出版服务。

The incidence and mortality rates of cancer are increasing every year worldwide but the survival rate of cancer patients is still unsatisfactory. Therefore, it is necessary to further elucidate the molecular mechanisms involved in tumor development and drug resistance to improve cancer cure or survival rates. In recent years, autophagy has become a hot topic in the field of oncology research, which plays a double-edged role in tumorigenesis, progression, and drug resistance. Meanwhile, long non-coding RNA (lncRNA) has also been shown to regulate autophagy, and the two-sided nature of autophagy determines the dual regulatory role of autophagy-related lncRNAs (ARlncRNAs). Therefore, ARlncRNAs can be effective therapeutic targets for various cancers. Furthermore, the high abundance and stability of ARlncRNAs in tumor tissues make them promising biomarkers. In this review, we summarized the roles and mechanisms of ARlncRNAs in tumor cell proliferation, apoptosis, migration, invasion, drug resistance, angiogenesis, radiation resistance, and immune regulation. In addition, we described the clinical significance of these ARlncRNAs, including as biomarkers/therapeutic targets and their association with clinical drugs.© 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.